



Press Release

OncoMethylome's Commercial Partner Veridex Licenses Prostate Cancer Methylation Technology to Laboratory Corporation of America® Holdings

Liege (Belgium) – May 30, 2007, 8:00 am CET – OncoMethylome Sciences announced today that its commercial partner Veridex, LLC, granted a license to Laboratory Corporation of America® Holdings (LabCorp®) which permits LabCorp to commercialize nucleic acid testing technology for detecting the presence of a key tissue marker in prostate cancer, methylated GST-Pi.

The prostate cancer marker and methylation technology required to detect it were initially developed by OncoMethylome Sciences and were licensed to Veridex in a commercial deal that was announced on January 19, 2005. LabCorp is the first full-service, national clinical laboratory in the U.S. to access this important new technology. Terms of the agreement were not disclosed.

"I am pleased that this agreement between Veridex and LabCorp brings OncoMethylome methylation technology one step closer to commercialization" said Herman Spolders, CEO of OncoMethylome Sciences.

About Methylation

Methylation is a natural control mechanism that regulates gene expression in DNA. Abnormal methylation of certain genes, such as tumor suppressor genes, can silence gene expression and is often associated with cancer development. OncoMethylome owns proprietary technology that is highly sensitive and capable of detecting cancer in early stages of cancer development. In the case of prostate cancer, this technology identifies methylation at genes that have been shown to be associated with prostate cancer.

About OncoMethylome Sciences

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing patent-protected gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, Schering-Plough Corp., Chemicon International Inc., and EXACT Sciences Corp. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).

For more information please contact:

Lucija Turcinov

Tel. +32-479-801-902

Lucija.Turcinov@oncomethylome.com

or visit: www.oncomethylome.com